Role of the Transcription Factor NRF2 in Neurodegenerative Disorders

A special issue of Antioxidants (ISSN 2076-3921). This special issue belongs to the section "Health Outcomes of Antioxidants and Oxidative Stress".

Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 2532

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Biochemistry, School of Medicine, Universidad Autónoma de Madrid, 28040 Madrid, Spain
2. Instituto de Investigaciones Biomédicas “Alberto Sols” UAM-CSIC, Arturo Duperier 4, 28029 Madrid, Spain
3. Institute Teófilo Hernando for Drug Discovery, Universidad Autónoma de Madrid, 28029 Madrid, Spain
4. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28031 Madrid, Spain
Interests: Parkinson’s disease; tauopathies; Amyotrophic lateral sclerosis; NRF2; mitochondria; neuroinflammation; oxidative stress

Special Issue Information

Dear Colleagues,

The aging of the population poses a growing burden in society. This is associated with the increase in disability and diseases that have a high impact on health care, on patients and their families. Likewise, aging is associated with the appearance of neurodegenerative diseases. Although each of these diseases has its own characteristics, they all share altered proteostasis, oxidative stress and neuroinflammation. In recent years, it has been described that the transcription factor NRF2 is involved in the modulation of all these processes, becoming a pleiotropic factor. Therefore, understanding the involvement of NRF2 in the different mechanisms associated with neurodegeneration may be of vital importance in establishing new therapeutic targets.

As guest editor, I invite you to contribute to this Special Issue, whose focus will be the role of NRF2 in neurodegenerative disorders.

We also invite researchers in the field and the participants of The COST Action CA20121, Bench to Bedside Transition for Pharmacological regulation of NRF2 in non-communicable diseases (BenBedPhar) to submit their latest research findings to this Special Issue. We look forward to reading your contributions.

Prof. Dr. Isabel Lastres-Becker
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Alzheimer’s disease
  • down syndrome
  • parkinson’s disease
  • Huntington’s disease
  • amyotrophic lateral sclerosis
  • ischemia
  • oxidative stress
  • neuroinflammation
  • proteostasis
  • mitochondria

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

25 pages, 3046 KiB  
Review
Aging, NRF2, and TAU: A Perfect Match for Neurodegeneration?
by Mirjam Brackhan, Marina Arribas-Blazquez and Isabel Lastres-Becker
Antioxidants 2023, 12(8), 1564; https://doi.org/10.3390/antiox12081564 - 04 Aug 2023
Cited by 4 | Viewed by 2028
Abstract
Although the trigger for the neurodegenerative disease process is unknown, the relevance of aging stands out as a major risk for the development of neurodegeneration. In this review, we highlighted the relationship between the different cellular mechanisms that occur as a consequence of [...] Read more.
Although the trigger for the neurodegenerative disease process is unknown, the relevance of aging stands out as a major risk for the development of neurodegeneration. In this review, we highlighted the relationship between the different cellular mechanisms that occur as a consequence of aging and transcription factor nuclear factor erythroid-2-related factor 2 (NRF2) and the connection with the TAU protein. We focused on the relevance of NRF2 in the main processes involved in neurodegeneration and associated with aging, such as genomic instability, protein degradation systems (proteasomes/autophagy), cellular senescence, and stem cell exhaustion, as well as inflammation. We also analyzed the effect of aging on TAU protein levels and its aggregation and spread process. Finally, we investigated the interconnection between NRF2 and TAU and the relevance of alterations in the NRF2 signaling pathway in both primary and secondary tauopathies. All these points highlight NRF2 as a possible therapeutic target for tauopathies. Full article
(This article belongs to the Special Issue Role of the Transcription Factor NRF2 in Neurodegenerative Disorders)
Show Figures

Graphical abstract

Back to TopTop